32 Introduction: The emergence of tuberculosis (TB) and diabetes mellitus (DM) co-epidemic, threatens the 33 gains made in fighting the prevalence of these two diseases. As a result, in 2011, the World Health 34 Organization (WHO) and International Union against Lung Disease (IUALD), launched a framework to 35 address the growing TB-DM co-epidemic across the world. The proposed review study is aimed at mapping 36 evidence on the implementation of the WHO collaborative framework for the management of TB-DM using 37 a systematic scoping review.
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Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence. [9] gives 5 clear steps to be used to explore core concepts 120 in a specific research area. These steps are: identifying the research question, identifying relevant studies, 121 study selection, charting the data, collating, summarizing and reporting the results. This process is 122 expected to help identify the existing evidence on the research area. Additionally, analysis and 123 presentation of findings will be guided by the Preferred Reporting Items for Systematic Reviews and 124 Meta-Analysis extension for Scoping Reviews (PRISMA-ScR) [ Headings) terms will be included in the search. In conducting the electronic search, proposed 141 combinations of keywords to be used include : 'Diabetes', 'Type 2Diabetes', 'Tuberculosis',
142
"Comorbidity", "Implementation", "Framework". Studies will be identified by searching literature that 143 that was published in any language from 2011 to 2019. Articles on Type 1 diabetes will be excluded 144 because that condition does not share the socioeconomic, environmental and behavioral factors with 145 tuberculosis. Searches will be documented, detailing the date, search engine, keywords, and number of publications retrieved. The search strategies will be piloted to check the appropriateness of the selected 147 databases and key words. Table 2 below illustrates how the electronic data search will be recorded.
148 Table 2 : Pilot search strategy in PubMed database. The eligibility criteria will be developed to ensure specific information relating to the research question is 152
included in the studies 153
Inclusion criteria 154 We will include studies that meet the following criteria: 
165
The eligibility criteria will guide the researcher in conducting the title screening. Studies that qualify will 166 be compiled into a library using the Endnote reference management software. Duplicated articles will be 167 deleted from the EndNote library. The final list of compiled articles will be shared with two other 168 reviewers who will conduct both abstract and full screening into two categories "excluded" and 169 "included" according to the inclusion criteria detailed above. The services of the University of KwaZulu-
170
Natal Library will be sought to source articles that are not available online, or alternatively full text may 171 be requested from the authors. During the abstract screening stage, categorisation by the two reviewers 172 will be compared. In the event of any disagreement, the reviewers will discuss till an agreement is 173 reached. At the full text stage, a third reviewer will be engaged as a decider on any unresolved disputes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
176
Screening of the results and reporting will follow the Preferred Reporting Items for Systematic reviews 177 and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) steps listed below:
178 Objectives 4
Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.
Protocol and registration 5
Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.
Eligibility criteria 6
Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.
Information sources* 7
Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.
Search 8 Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.
Selection of sources of evidence 9
State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.
Data charting process 10
Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.
Source: Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) [10] 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   SECTION  ITEM  PRISMA-ScR CHECKLIST ITEM   Data items  11 List and define all variables for which data were sought and any assumptions and simplifications made.
Critical appraisal of individual sources of evidence §
12
If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).
Synthesis of results 13
Describe the methods of handling and summarizing the data that were charted.
Selection of sources of evidence 14
Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.
Characteristics of sources of evidence 15
For each source of evidence, present characteristics for which data were charted and provide the citations.
Critical appraisal within sources of evidence 16
If done, present data on critical appraisal of included sources of evidence (see item 12).
Results of individual sources of evidence 17
For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.
Synthesis of results 18
Summarize and/or present the charting results as they relate to the review questions and objectives.
Summary of evidence 19
Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.
Limitations 20
Discuss the limitations of the scoping review process.
Conclusions 21
Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.
Funding 22
Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.
180
Source: Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping 181
Reviews (PRISMA-ScR) [10]
183
Charting the data 184 To extract information in line with the aim of this study, an analytical method will be used. We will 185 develop a form electronically, using google forms, pre-test it and use feedback to refine the tool. During
186
data extraction, all articles reviewed and excluded will be tracked (Table 4) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Collating, summarizing and reporting of results
192
When the extraction of data is completed, the results from existing studies will be summarized and 193 presented in a narrative account This summary will be analyzed using thematic content analysis. Data 194 extracted will be structured around the following outcomes: Bidirectional screening of TB and DM,
195
Mechanisms for TB and DM collaborative activities, and Co-management of TB/DM comorbidity.
196
Emerging themes will also be coded using NVIVO software version 10 [11]. The themes emerging from 197 the analysis will be examined in order to determine whether they address the research questions.
198 Furthermore, the researcher will explore the linkages between the findings, and the study aim and the 199 implications for future research, policy and practice.
200
Quality appraisal 201 The quality of the studies will be appraised using the mixed method appraisal tool (MMAT)-Version 202 2018 [12] . The tool is used to assess the risk of bias of the included studies. The tool will be utilized to findings of the scoping review will generate important information necessary to support initiatives aimed 220 at curtailing the rising tide of high TB prevalence and DM rate [1] . The findings of this study may be of 221 interest to policy makers and stakeholders involved in the implementation of the prevention, care and 222 control strategies against the TB and DM, including the health systems strengthening. In addition, the 223 findings of this study will be of interest to researchers, as it will highlight the gaps in evidence that may 224 require further empirical investigation.
Conclusion

226
It is expected that the results of this systematic scoping review may be beneficial to stakeholders involved Data Availability 245 We have duly cited all studies and data is presented in a form of references.
246
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50 Ethics and Dissemination: The study did not require ethics approval because it is a scoping review 51 protocol. Findings from this study will be disseminated by print and electronic mediums. will be piloted to check the appropriateness of the selected databases and keywords. Table 2 below 148 illustrates how the electronic data search will be recorded.
149 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The eligibility criteria will be developed to ensure specific information relating to the research question is 153
included in the studies. 154 155
Inclusion criteria 156
We will include studies that meet the following criteria: 
165
 Studies before 2011.
166
 Studies on TB/HIV.
167
The eligibility criteria will guide the researcher in conducting the title screening. Studies that qualify will 168 be compiled into a library using the Endnote reference management software. Duplicated articles will be 169 deleted from the EndNote library. The final list of compiled articles will be shared with two other 170 reviewers who will conduct both abstract and full screening into two categories "excluded" and 171 "included" according to the inclusion criteria detailed above. The services of the University of KwaZulu-
172
Natal Library will be sought to source articles that are not available online, or alternatively, the full text 173 may be requested from the authors. During the abstract screening stage, categorisation by the two 174 reviewers will be compared. In the event of any disagreement, the reviewers will discuss until an 175 agreement is reached. At the full text stage, a third reviewer will be engaged as a decider on any 176 unresolved disputes. Details of the process: date of search, database, keywords, number of studies and 177 number of eligible studies will be comprehensively documented.
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Screening of the results and reporting will follow the Preferred Reporting Items for Systematic reviews 179 and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) [11] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Charting the data 181 To extract information in line with the aim of this study, an analytical method will be used. We will 182 develop a form electronically, using google forms, pre-test it and use feedback to refine the tool. During
183
data extraction, all articles reviewed and excluded will be tracked (Table 3. 184 185 186 Collating, summarizing and reporting of results
190
When the extraction of data is completed, the results from existing studies will be summarized and 191 presented in a narrative account. This summary will be analyzed using thematic content analysis. Data 192 extracted will be structured around the following outcomes: Bidirectional screening of TB and DM,
193
194
Emerging themes will also be coded using NVIVO software version 10 [13]. The themes emerging from 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 the analysis will be examined in order to determine whether they address the research questions.
196 Furthermore, the researcher will explore the linkages between the findings, and the study's aim and the 197 implications for future research, policy, and practice.
198
Quality appraisal 199 The quality of the studies will be appraised using the mixed method appraisal tool (MMAT)-Version
. The tool is used to assess the risk of bias of the included studies. The tool will be utilized to 201 assess the selected articles under the following groupings: the appropriateness of the aim of the study,
202
adequacy of methodology, study design, data collection, data analysis, the presentation of findings,
203
authors' discussions and conclusions. Scores will be allocated to determine the quality of the included 204 studies. The quality of the article will be determined from the examination of the above-mentioned 205 aspects.
206
Discussion
207
The scoping review is aimed at mapping existing evidence and summarizing the findings as presented Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.
Information sources* 7
5-6 Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.
Search 8 6 Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.
Selection of sources of evidence 9 N/A State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.
Data charting process 10 N/A Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.
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44
(Academic search complete, health source: nursing/academic edition, CINAHL with full text), and the 45 WHO library will be used to source literature. The researcher will perform title screening of articles using 46 keywords in the databases, and two independent reviewers will then screen abstracts and full articles. The screening will be guided by the inclusion and exclusion criteria. The Mixed Method Appraisal Tool
48
(MMAT) version 2018 will be used to examine the quality of studies to be included. The findings will be 49 analyzed using the thematic content analysis approach and the results presented in the form of a narrative 50 report.
51 Ethics and Dissemination: The study did not require ethics approval because it is a scoping review 52 protocol. Findings from this study will be disseminated by print and electronic mediums. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
140
We will search for articles using keywords and Boolean terms AND/OR. Additionally, a combination of 141 the appropriate MeSH (Medical Subject Headings) terms will be included in the search. In conducting the 142 'electronic search, the proposed combinations of keywords to be used include: "Diabetes," "Type 2 143 Diabetes," "Tuberculosis," "Comorbidity," "Implementation," "Framework." Studies will be identified by 
148
The search strategies will be piloted to check the suitability of the selected databases and keywords. An 149 illustration of how the electronic data search will be recorded is shown in Table 2 . The eligibility criteria will be developed to ensure, that specific information relating to the research 158 questions are included in the studies. 159 160
Inclusion criteria 161
172
The eligibility criteria will guide the researcher in conducting the title screening. Studies that qualify will 173 be compiled into a library using the Endnote reference management software. Duplicated articles will be 174 deleted from the EndNote library. The final list of compiled articles will be shared with two other reviewers 175 who will conduct both abstract and full screening into two categories "excluded" and "included" according 176 to the inclusion criteria detailed above. The service of the University of KwaZulu-Natal Libraries will be 177 sought to source articles that are not available online, or the full text may be requested from the authors.
178
During the abstract screening stage, categorization by the two reviewers will be compared. In the event of 179 any disagreement, the reviewers will discuss until an agreement is reached. At the full-text stage, a third 180 reviewer will be engaged as a decider on any unresolved disputes. Details of the process: date of search, 181 database, keywords, number of studies and number of eligible studies will be comprehensively documented. Screening of the results and reporting will follow the Preferred Reporting Items for Systematic reviews and 183 Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) [11] .
184
Charting the data 185 To extract information in line with the aim of this study, an analytical method will be used. We will develop 186 a form electronically, using google forms, pre-test it, and use feedback to refine the tool. During data 187 extraction, all articles reviewed and excluded will be tracked (Table 3) . Collating, summarizing and reporting of results
189
192
When the extraction of data is completed, the results from existing studies will be summarized and 193 presented in a narrative account. This summary will be analyzed using thematic content analysis. Data 194 extracted will be structured around the following outcomes: Bidirectional screening of TB and DM,
195
Mechanisms for TB and DM collaborative activities, and Co-management of TB/DM comorbidity. Emerging themes will also be coded using NVIVO software version 10 [13]. The themes emerging from 197 the analysis will be examined to determine whether they address the research questions. Furthermore, the 198 researcher will explore the linkages between the findings, study aim, and the implications for future 199 research, policy, and practice.
200
Quality appraisal 201 The quality of the studies will be appraised using the mixed method appraisal tool (MMAT)-Version 2018
202
[14]. The tool is used to assess the risk of bias of the included studies. The tool will be utilized to assess the 203 selected articles under the following groupings: the appropriateness of the aim of the study, adequacy of 204 methodology, study design, data collection, data analysis, the presentation of findings, authors' discussions, 205 and conclusions. Scores will be allocated to determine the quality of the included studies. The quality of 206 the selected articles will be determined from the examination of the aspects mentioned above.
207 Patient and Public Involvement: The conception, design, and planning of this study did not directly 208 include patients or the public.
209
Ethics and Dissemination: The study did not require ethics approval because it is a scoping review 210 protocol. Findings from this study will be disseminated by print and electronic mediums. involved in the implementation of the prevention, care, and control strategies for TB and DM, including 235 the health systems strengthening. Also, the findings of this study will be of interest to researchers, as it will 236 highlight the gaps in evidence that may require further empirical investigation.
211
Discussion
237
Study Status: We expect to report the finding of this review by the end of April 2020. Identify the report as a scoping review.
Structured summary 2 2-9 Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.
Rationale 3
8-9
Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.
Objectives 4 5
Protocol and registration 5 N/A Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.
Eligibility criteria 6 6
Information sources* 7 5 Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.
Data charting process 10 N/A Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators. Selection of sources of evidence 14 N/A Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.
Characteristics of sources of evidence 15 N/A For each source of evidence, present characteristics for which data were charted and provide the citations.
Critical appraisal within sources of evidence 16 N/A If done, present data on critical appraisal of included sources of evidence (see item 12).
Results of individual sources of evidence 17 N/A For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
Synthesis of results
